Periodic Reporting for period 1 - STIMULUS (Speckle Technology and Digital Biomarkers of Microvascular Function for Monitoring Cardiovascular Diseases)
Reporting period: 2023-10-01 to 2024-09-30
Over 60 million people in the EU live with cardiovascular diseases (CVDs), at an annual economic cost of +210B€. Despite being largely preventable, CVDs cause more than 18.5 million deaths every year. To combat this, we develop new instruments for assessing adverse changes in microcirculatory status linked to hypertension, chronic kidney disease (CKD) and heart failure (HF), leading to earlier detection of CVDs. The instruments are developed and validated in clinical trials. We integrate two state-of-the-art technologies leading to a novel innovation, 3D speckle tissue monitoring. In addition, we demonstrate a direct use-case for unobtrusive monitoring in a smarttoilet application.
Global remote patient monitoring (RPM) systems market is expected to surpass 5 B$ by 2030 with CAGR of 20%. The demand for the RPM systems is rapidly growing among the old age population. Monitoring innovations targeting this group can reduce hospitalization and costly chronic conditions. Furthermore, the technology is closely linked to wearable remote monitoring. The global wearable technology market is expected to grow to 392 B$ by 2030 with CAGR of 13.9%. The opportunity is significant as the number of wearable users currently exceeds 1 billion globally and the developed technology targets similar markets. We currently estimate that with the new instrument and digital biomarkers we can reduce the healthcare burden by over 30% by preventing CVDs. Additionally, we are aiming to identify citizens at risk of developing hypertension, CKD and/or HF and by timely intervention, we expect to reduce indirect healthcare costs by over 20%. In conclusion, our solution will integrate two existing state-of-the-art methods and provide clearly new monitoring techniques to assess the microcirculatory status, revealing early signs of CVDs. We will provide an innovative solution to emerging digital unobtrusive health markets while helping the over 60 million Europeans suffering from CVDs.
Global remote patient monitoring (RPM) systems market is expected to surpass 5 B$ by 2030 with CAGR of 20%. The demand for the RPM systems is rapidly growing among the old age population. Monitoring innovations targeting this group can reduce hospitalization and costly chronic conditions. Furthermore, the technology is closely linked to wearable remote monitoring. The global wearable technology market is expected to grow to 392 B$ by 2030 with CAGR of 13.9%. The opportunity is significant as the number of wearable users currently exceeds 1 billion globally and the developed technology targets similar markets. We currently estimate that with the new instrument and digital biomarkers we can reduce the healthcare burden by over 30% by preventing CVDs. Additionally, we are aiming to identify citizens at risk of developing hypertension, CKD and/or HF and by timely intervention, we expect to reduce indirect healthcare costs by over 20%. In conclusion, our solution will integrate two existing state-of-the-art methods and provide clearly new monitoring techniques to assess the microcirculatory status, revealing early signs of CVDs. We will provide an innovative solution to emerging digital unobtrusive health markets while helping the over 60 million Europeans suffering from CVDs.
STIMULUS project consortium develops new non-invasive, convenient, low-cost and easy-to-use imaging technology that can measure new digital biomarkers from microcirculation for early detection of cardiovascular diseases. The novel technology will enable earlier detection of heart failure and chronic kidney disease, which will substantially decrease cardiovascular events in the European population.
Development of new integrated solution and clinical trials
For both heart failure and chronic kidney disease patients, it is important to diagnose microvascular dysfunction and monitor the deterioration of microvascular function in early phases of the disease progress. Our proposed technology HEMI-speckle system is an integrated solution of two existing prototypes, namely, the multi-spectral optical sensory system and the speckle plethysmography (SPG) system. To understand the diagnostic value of these technologies for both HF and CKD populations, two clinical trials will be executed. At the same time, the new integrated solution will be developed. Adjustment of the existing individual technologies can be made prior to conduct of the validation trial to guarantee a proper conduct of the trial in a patient population in a clinical setting. Lessons learnt from these clinical trials can be used a) for the development of the integrated HEMI-speckle system, b) to identify new digital biomarkers from the individual and integrated technology, c) to analyse the sensitivity and specificity of the two technologies for each population separately, and d) to prove the validity of the technologies for the early assessment of microvascular function in the target population. A third clinical trial will run in a later phase, when the HEMI-speckle prototype is ready. In this trial, the new technology will be verified on healthy volunteers and hypertensives, after the validation of the underlying technologies on a relevant patient population has been done. The additional new digital biomarkers obtained from the unique combination of the two individual technologies can be explored in this phase.
Health technology assessment
One of the key roles of Technology Assessment is to provide prospective knowledge about the possible or probable consequences of new and emerging technologies. In the process, intended and non-intended impacts of the technology application are identified. Anticipating the spectrum of possible consequences of technology, at an early stage, helps to make good use of the potential of progress and to be able to minimize risks or even to avoid them.
Development of new integrated solution and clinical trials
For both heart failure and chronic kidney disease patients, it is important to diagnose microvascular dysfunction and monitor the deterioration of microvascular function in early phases of the disease progress. Our proposed technology HEMI-speckle system is an integrated solution of two existing prototypes, namely, the multi-spectral optical sensory system and the speckle plethysmography (SPG) system. To understand the diagnostic value of these technologies for both HF and CKD populations, two clinical trials will be executed. At the same time, the new integrated solution will be developed. Adjustment of the existing individual technologies can be made prior to conduct of the validation trial to guarantee a proper conduct of the trial in a patient population in a clinical setting. Lessons learnt from these clinical trials can be used a) for the development of the integrated HEMI-speckle system, b) to identify new digital biomarkers from the individual and integrated technology, c) to analyse the sensitivity and specificity of the two technologies for each population separately, and d) to prove the validity of the technologies for the early assessment of microvascular function in the target population. A third clinical trial will run in a later phase, when the HEMI-speckle prototype is ready. In this trial, the new technology will be verified on healthy volunteers and hypertensives, after the validation of the underlying technologies on a relevant patient population has been done. The additional new digital biomarkers obtained from the unique combination of the two individual technologies can be explored in this phase.
Health technology assessment
One of the key roles of Technology Assessment is to provide prospective knowledge about the possible or probable consequences of new and emerging technologies. In the process, intended and non-intended impacts of the technology application are identified. Anticipating the spectrum of possible consequences of technology, at an early stage, helps to make good use of the potential of progress and to be able to minimize risks or even to avoid them.
The global remote patient monitoring systems market was estimated at USD 965 million in 2021 and is expected to surpass USD 5 billion by 2030, poised to grow at a compound annual growth rate (CAGR) of 20% during the forecast period 2022 to 2030. The increasing adoption of digital technologies in the global healthcare industry is significantly driving the remote patient monitoring (RPM) systems market. The demand for the RPM systems is rapidly growing among the old age population, as this age group needs continuous monitoring of their health conditions. The number of people aged 60 years or above is expected to reach 2.1 billion by 2050. Monitoring innovations targeting this group can reduce hospitalization and costly chronic conditions, and hence help reduce the healthcare costs for the citizens. Furthermore, the technology is closely linked to wearable remote monitoring, mostly including photolethysmographic devices. The global wearable technology market is expected to grow to 392 B$ by 2030 with CAGR of 13.9%. The opportunity is significant as the number of existing users for wearables currently exceeds 1 billion globally and the developed technology targets similar use-cases and form factors. As the global prevalence of cardiovascular diseases is rising, our unique innovation to detect cardiovascular diseases early will have great market potential. To protect future commercial interests, one patent for the technology this project is based on, has already been obtained, and two patents are currently pending. Also, the novel technology developed in this project will be similarly protected.